- Public awareness of cardiovascular disease prevention in Korea
-
Kim E, Jung CH, Rhee EJ, Noh J, Lee JH, Park HJ, Park S, Ihm SH, Lee WY, Kim HC
- KMID: 2534488
- Cardiovasc Prev Pharmacother.
- 2022 Oct;4(4):149-157.
- doi: 10.36011/cpp.2022.4.e20
Background: The burden of cardiovascular disease (CVD) is significant in Korea. Ultimately, public knowledge and awareness of CVD risk factors and prevention are essential to reduce its burden. Hence, this... -
- CITED
-
- Close
- SHARE
-
- Close
- The effects and side effects of liraglutide as a treatment for obesity
-
Ha J, Yu J, Lee J, Kim HS
- KMID: 2534487
- Cardiovasc Prev Pharmacother.
- 2022 Oct;4(4):142-148.
- doi: 10.36011/cpp.2022.4.e18
The incidence of obesity is increasing throughout the world, including Korea. Liraglutide, the main purpose of which is glucose control, has recently gained significant attention due to its additional effect... -
- CITED
-
- Close
- SHARE
-
- Close
- The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence?
-
Koo DJ, Lee WY
- KMID: 2534486
- Cardiovasc Prev Pharmacother.
- 2022 Oct;4(4):132-141.
- doi: 10.36011/cpp.2022.4.e17
Nonalcoholic fatty liver disease (NAFLD), which has recently undergone a change in its definition and acronym to “metabolic dysfunction associated fatty liver disease (MAFLD),” is clinically significant as an increasingly... -
- CITED
-
- Close
- SHARE
-
- Close
- Metabolically healthy obesity: it is time to consider its dynamic changes
-
Cho YK, Jung CH
- KMID: 2534485
- Cardiovasc Prev Pharmacother.
- 2022 Oct;4(4):123-131.
- doi: 10.36011/cpp.2022.4.e19
Obesity reduces life expectancy, lowers quality of life, and causes numerous cardiometabolic diseases and some cancers. However, the individual risk of developing obesity-associated comorbidities is highly variable and cannot be... -
- CITED
-
- Close
- SHARE
-
- Close
